DIETEVOME: Deciphering the Role of Dietary Fatty Acids on Extracellular Vesicles-mediated Intercellular Communication

Sponsor
University of Seville (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06051461
Collaborator
Spanish National Research Council (Other)
40
1
2
46
0.9

Study Details

Study Description

Brief Summary

Dietary interventions have been consistently proposed as a part of a comprehensive strategy to lower the incidence and severity of atherosclerosis and coronary vascular disease. Excessive comsumption of fats enriched in saturated fatty acids (SFAs) is associated with an increased risk of atherosclerosis and other cardiovascular diseases (CVD). In contrasts, replacement of SFAs with monounsaturated fatty acids (MUFAs) and omega-3 long chain polyunsaturated fatty acids (ω3-LCPUFAs) has been reported to be inversely associated with risk of atherosclerosis. This is partly due to the ability of MUFAs (and ω3-LCPUFAs) to modulate lipoprotein composition, oxidation state, and consequently their functionality, among others. While most of the nutritional studies have focused on elucidating the mechanisms by which dietary fats affect lipoprotein particles, little or nothing is known about the regulatory effect of dietary fatty acids on extracellular vesicles (EVs). EVs are small phospholipid particles that convey molecular bioactive cargoes and play essential roles in intercellular communication and, hence, a multifaceted role in health and disease. For the first time, the purpose of this project is to establish whether the type of major fatty acids present on a diet (SFAs, MUFAs, or ω3-LCPUFAs) may alter the structure, cargo, and functionality of postprandial- and long-term-EVs. In the precision nutrition era, the investigators expect to offer a new insight on EVs and their relationship with dietary fatty acids through the following objectives: 1) To map changes in the lipidome, proteome, microtranscriptome, and functional properties of circulating EVs in healthy subjects and patients with metabolic syndrome (MetS) both at fasting and at postprandial state upon a challenge of a meal rich in SFAs, MUFAs, and ω3-LCPUFAs; 2) To analyse the contribution of postprandial triacylglyceride-rich lipoproteins (TRL) on EVs-mediated intercellular communication in a fatty acid-dependent manner; and 3) To determine the influence of diets rich in SFAs, MUFAs, and ω3-LCPUFAs on EVs in an animal model of atherosclerosis in the setting of MetS. Collectively, this project will provide fundamental insight into EV biology, and remarks the clinical and functional relevance and divergent consequences of dietary fatty acids in health and disease.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Oral lipid emulsions
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Basic Science
Official Title:
Deciphering the Role of Dietary Fatty Acids on Extracellular Vesicles-mediated Intercellular Communication and Their Implication in Atherosclerosis and Metabolic Syndrome: a Multi-omics Approach to Precision Nutrition
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
Sep 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Metabolic Syndrome patients

Dietary Supplement: Oral lipid emulsions
The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFAs) or refined olive oil (MUFAs) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA (ω3-LCPUFAs).

Experimental: Healthy patients

Dietary Supplement: Oral lipid emulsions
The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFAs) or refined olive oil (MUFAs) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA (ω3-LCPUFAs).

Outcome Measures

Primary Outcome Measures

  1. Evolution of cytokines in postprandial state [Up to 6 hours]

    Pro-inflammatory and anti-inflammatory cytokines, including NFα, IL-1β, IL-6, IL-8, IL-10, ICAM-1, MCP-1, leptin, and adiponectin, in plasma will be measured using appropriate methods (EIA, ELISA, and/or Bioplex multiplex system) (mg/dl).

  2. Evolution of inflammatory markers in postprandial state. [Time Frame: Up to 6 hours] [Up to 6 hours]

    The acute phase protein (hsCRP), PAI-1, fibrinogen, transferrin, albumin, and myeloperoxidase (MPO) will be measured using appropriate methods (EIA, ELISA, and/or Bioplex multiplex system) (mg/dl).

  3. Effect of EVs on gene expression in PBMCs [Up to 6 hours]

    PBMCs will be isolated from the subjects' peripheral blood and treated with autologous circulating EVs for different times.

  4. EV proteome [Up to 6 hours]

    The quantification of exosome-derived proteins will be performed by nLC-MS/MS

  5. EV lipidome [Up to 6 hours]

    The analysis of intact lipids derived from exosomes will be performed by LC-MS

  6. Ev microtranscriptome [Up to 6 hours]

    Enriched RNA and miRNA derived from exosomes will be determined by Next Generation Sequencing (NGS)

Eligibility Criteria

Criteria

Ages Eligible for Study:
35 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

• Clinical diagnosis of metabolic syndrome

Exclusion Criteria:
  • Allergy to dairy products

  • Allergy to fish oil

  • Vegetarian

  • Tobacco smoker

  • Current or recent (<4 wk) use of fish oil supplements or more than four times fish/week

  • Received innoculations within 2 mo of starting the study or planned to during the study

  • Donated or intended to donate blood from 2 mo before the study till 2 mo after the study

  • Unstable body weight (no weight gain/loss >3 kg)

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Seville Seville Spain 41009

Sponsors and Collaborators

  • University of Seville
  • Spanish National Research Council

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sergio Montserrat de la Paz, Professor, University of Seville
ClinicalTrials.gov Identifier:
NCT06051461
Other Study ID Numbers:
  • US
First Posted:
Sep 25, 2023
Last Update Posted:
Sep 25, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 25, 2023